GLOW Peptide Blend 70mg – Research Compound

GLOW peptide blend is a three-component research formulation combining GHK-Cu, BPC-157, and TB-500 in a single 70mg research-grade vial. The formulation is supplied as lyophilized powder and is intended exclusively for controlled laboratory and scientific research.

The GLOW 70mg formulation consists of 50mg GHK-Cu, 10mg BPC-157, and 10mg TB-500. Current research-compound listings consistently identify this 50:10:10 composition as the standard 70mg GLOW formulation.

The three components represent distinct research materials that can be investigated individually or as part of a multi-component formulation. This makes the GLOW research peptide relevant to laboratory studies involving cellular signaling, extracellular matrix biology, peptide interactions, and related molecular pathways.

GLOW 70mg Product Specifications

• Product: GLOW Blend
• Total Strength: 70 mg
• GHK-Cu: 50 mg
• BPC-157: 10 mg
• TB-500: 10 mg
• Purity: ≥99%
• Grade: Research Grade
• Format: Multidose Vial
• Appearance: Lyophilized Powder
• Storage: Store refrigerated at 2°C–8°C. Protect from light and moisture.

The listed formulation totals 70mg per vial. Researchers should consult the applicable product documentation and batch-specific Certificate of Analysis (COA), where available, for additional analytical information.

GLOW Peptide Blend Composition

GHK-Cu – 50mg

GHK-Cu is the primary component of the GLOW formulation, representing 50mg of the total 70mg composition. This copper-containing peptide is widely investigated in laboratory research involving extracellular matrix biology, cellular signaling, connective-tissue-related pathways, and molecular interactions.

Within the GHK-Cu BPC-157 TB-500 blend, GHK-Cu provides the copper-peptide component for research models examining cellular and extracellular processes.

BPC-157 – 10mg

BPC-157 is included at 10mg in the GLOW formulation. It has been investigated in preclinical and laboratory research involving cellular signaling, angiogenesis-related pathways, and tissue biology.

Its inclusion alongside GHK-Cu and TB-500 provides researchers with a multi-component research formulation for comparative and exploratory laboratory studies.

TB-500 – 10mg

TB-500 is included at 10mg. Research involving TB-500 and related thymosin-beta pathways has examined cellular and molecular processes relevant to tissue and cytoskeletal biology.

Researchers who require the individual compound can also explore the TB-500 research peptide available separately from BioMatrix Compounds.

GLOW Research Peptide Applications

The GLOW research peptide formulation can be studied in controlled laboratory environments involving areas such as:

• Skin biology research
• Extracellular matrix biology
• Collagen-related research
• Elastin-related research
• Cellular signaling
• Peptide interaction studies
• Molecular and biochemical research
• Cellular response pathways
• Tissue remodeling research
• Comparative multi-peptide studies

These terms describe areas of scientific investigation rather than established therapeutic effects. While individual components have been investigated in preclinical research, findings involving individual compounds should not automatically be interpreted as evidence for the combined GLOW formulation.

The scientific literature surrounding these emerging peptide compounds varies by compound, experimental model, and research question. Researchers should therefore evaluate primary literature and appropriate experimental evidence when designing laboratory studies.

GLOW 70mg Research-Grade Format

GLOW is supplied as a lyophilized powder in a multidose vial, providing a defined three-component research formulation in one product.

The 70mg formulation follows a 50mg GHK-Cu, 10mg BPC-157, and 10mg TB-500 composition. This formulation is also reflected across current research-compound listings for GLOW 70mg.

The lyophilized format is designed for laboratory research workflows where researchers require a clearly identified research material. Product specifications, purity information, and available analytical documentation should be reviewed before incorporating the material into any laboratory protocol.

Quality and Storage

BioMatrix Compounds lists GLOW Blend at ≥99% purity and supplies it as a research-grade lyophilized powder.

For storage, keep the product refrigerated at 2°C–8°C and protect it from light and moisture. Researchers should always follow the current product documentation and applicable laboratory storage procedures.

Where available, batch-specific documentation such as a Certificate of Analysis can provide additional information regarding the tested material and should be reviewed alongside the product specifications.

Research Use Only

GLOW peptide blend is supplied exclusively for laboratory and scientific research purposes.

It is not intended for human consumption, veterinary use, medical use, therapeutic use, cosmetic use, food use, or diagnostic applications. The product is not represented as a drug or treatment and should not be used to diagnose, treat, cure, or prevent any disease.

Canadian customers should independently verify all applicable requirements concerning the purchase, possession, handling, storage, and research use of peptide compounds. Health Canada has issued advisories concerning unauthorized injectable peptide products and specifically identifies compounds including BPC-157, GHK-Cu, KPV, and TB-500 in its public communications.

For authoritative Canadian regulatory information, researchers can review the Health Canada peptide advisory.

By purchasing GLOW peptide blend, customers acknowledge that the product is supplied for legitimate laboratory research purposes and accept responsibility for ensuring that its purchase, possession, handling, storage, and use comply with all applicable federal, provincial, and local requirements.

For Research Use Only. Not for Human or Veterinary Use.